173 related articles for article (PubMed ID: 37037091)
1. Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications.
Bashraheel SS; Kheraldine H; Khalaf S; Moustafa AA
Biomed Pharmacother; 2023 Jun; 162():114676. PubMed ID: 37037091
[TBL] [Abstract][Full Text] [Related]
2. Metformin and Breast Cancer: Molecular Targets.
Faria J; Negalha G; Azevedo A; Martel F
J Mammary Gland Biol Neoplasia; 2019 Jun; 24(2):111-123. PubMed ID: 30903363
[TBL] [Abstract][Full Text] [Related]
3. Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes.
Dutta S; Shah RB; Singhal S; Dutta SB; Bansal S; Sinha S; Haque M
Drug Des Devel Ther; 2023; 17():1907-1932. PubMed ID: 37397787
[TBL] [Abstract][Full Text] [Related]
4. Convergence of IPMK and LKB1-AMPK signaling pathways on metformin action.
Bang S; Chen Y; Ahima RS; Kim SF
Mol Endocrinol; 2014 Jul; 28(7):1186-93. PubMed ID: 24877601
[TBL] [Abstract][Full Text] [Related]
5. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Menendez JA
Cell Cycle; 2009 Jan; 8(1):88-96. PubMed ID: 19106626
[TBL] [Abstract][Full Text] [Related]
6. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
7. Estrogen Receptor Is Required for Metformin-Induced Apoptosis in Breast Cancer Cells Under Hyperglycemic Conditions.
Sekar AP; Nurmala S; Matsuura E; Tan XW; Rahmasari R; Sauriasari R
Breast Cancer (Auckl); 2024; 18():11782234241240173. PubMed ID: 38779416
[TBL] [Abstract][Full Text] [Related]
8. Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways.
Ikhlas S; Ahmad M
Life Sci; 2017 Sep; 185():53-62. PubMed ID: 28755883
[TBL] [Abstract][Full Text] [Related]
9. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
Guppy A; Jamal-Hanjani M; Pickering L
Future Oncol; 2011 Jun; 7(6):727-36. PubMed ID: 21675836
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer.
Jaromy M; Miller JD
Eur J Pharmacol; 2021 Apr; 897():173956. PubMed ID: 33617821
[TBL] [Abstract][Full Text] [Related]
11. Metformin is synthetically lethal with glucose withdrawal in cancer cells.
Menendez JA; Oliveras-Ferraros C; Cufí S; Corominas-Faja B; Joven J; Martin-Castillo B; Vazquez-Martin A
Cell Cycle; 2012 Aug; 11(15):2782-92. PubMed ID: 22809961
[TBL] [Abstract][Full Text] [Related]
12. Metformin as an Anticancer Agent.
Vancura A; Bu P; Bhagwat M; Zeng J; Vancurova I
Trends Pharmacol Sci; 2018 Oct; 39(10):867-878. PubMed ID: 30150001
[TBL] [Abstract][Full Text] [Related]
13. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Martin-Castillo B; Menendez JA
Curr Mol Med; 2010 Oct; 10(7):674-91. PubMed ID: 20712585
[TBL] [Abstract][Full Text] [Related]
14. Metformin: taking away the candy for cancer?
Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes.
Chikermane SG; Sharma M; Abughosh SM; Aparasu RR; Trivedi MV; Johnson ML
Breast Cancer Res Treat; 2022 Oct; 195(3):421-430. PubMed ID: 35969285
[TBL] [Abstract][Full Text] [Related]
16. Metformin: from mechanisms of action to therapies.
Foretz M; Guigas B; Bertrand L; Pollak M; Viollet B
Cell Metab; 2014 Dec; 20(6):953-66. PubMed ID: 25456737
[TBL] [Abstract][Full Text] [Related]
17. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.
He X; Esteva FJ; Ensor J; Hortobagyi GN; Lee MH; Yeung SC
Ann Oncol; 2012 Jul; 23(7):1771-80. PubMed ID: 22112968
[TBL] [Abstract][Full Text] [Related]
18. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
19. Current understanding of metformin effect on the control of hyperglycemia in diabetes.
An H; He L
J Endocrinol; 2016 Mar; 228(3):R97-106. PubMed ID: 26743209
[TBL] [Abstract][Full Text] [Related]
20. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.
Corominas-Faja B; Quirantes-Piné R; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Martin-Castillo B; Micol V; Joven J; Segura-Carretero A; Menendez JA
Aging (Albany NY); 2012 Jul; 4(7):480-98. PubMed ID: 22837425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
